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Abstract
Aims/hypothesis In this study we aimed to replicate the
previously reported association between the glycaemic re-
sponse to metformin and the SNP rs11212617 at a locus that
includes the ataxia telangiectasia mutated (ATM) gene in
multiple additional populations.
Methods Incident users of metformin selected from the Dia-
betes Care System West-Friesland (DCS, n0929) and the
Rotterdam Study (n0182) from the Netherlands, and the
CARDS Trial (n0254) from the UK were genotyped for
rs11212617 and tested for an association with both HbA1c
reduction and treatment success, defined as the ability to
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Finally, a meta-analysis including data from literature was
performed.
Results In the DCS cohort, we observed an association
between rs11212617 genotype and treatment success on
metformin (OR 1.27, 95% CI 1.03, 1.58, p00.028); in the
smaller Rotterdam Study cohort, a numerically similar but
non-significant trend was observed (OR 1.45, 95% CI 0.87,
2.39, p00.15); while in the CARDS cohort there was no
significant association. In meta-analyses of these three
cohorts separately or combined with the previously pub-
lished cohorts, rs11212617 genotype is associated with
metformin treatment success (OR 1.24, 95% CI 1.04, 1.49,
p00.016 and OR 1.25, 95% CI 1.33, 1.38, p07.8×10
−6,
respectively).
Conclusions/interpretation A gene variant near ATM is sig-
nificantly associated with metformin treatment response in
type 2 diabetic patients from the Netherlands and the UK.
This is the first robustly replicated common susceptibility
locus found to be associated with metformin treatment
response.
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Abbreviations
AMPK AMP-activated protein kinase
ATM Ataxia telangiectasia mutated
CARDS Collaborative Atorvastatin Diabetes Study
DCS Diabetes Care System West-Friesland
DPP Diabetes Prevention Program
GoDARTS Genetics of Diabetes Audit and Research
Tayside
HWE Hardy–Weinberg equilibrium
LD Linkage disequilibrium
SNP Single-nucleotide polymorphism
UKPDS UK Prospective Diabetes Study
Introduction
Metformin is the first-choice treatment for type 2 diabetes
[1]. It mainly improves fasting glucose levels by decreasing
hepatic glucose production by inhibiting the mitochondrial
respiratory-chain complex [2, 3], leading to activation of the
AMP-activated protein kinase (AMPK) [4] through in-
creased cellular AMP [5]. Activation of the AMPK path-
ways was thought to be an important underlying mechanism
involved in the inhibition of hepatic gluconeogenesis by
metformin [6]; however, AMPK-independent glucose-
lowering effects of metformin have been described recently
[7], and therefore the exact molecular mechanism of action
remains unclear.
Our recent genome-wide association study revealed that
the single-nucleotide polymorphism (SNP) rs11212617, lo-
cated near the ataxia telangiectasia mutated (ATM) gene, is
associated with metformin treatment response [8]. It has
been shown in UK participants with type 2 diabetes mellitus
from the GoDARTS (Genetics of Diabetes Audit and Re-
search Tayside) and UKPDS (UK Prospective Diabetes
Study) cohorts (n03,920) that the minor C allele of
rs11212617 is associated with two successful treatment out-
comes: (1) the ability to achieve HbA1c values ≤7%
(53 mmol/mol); (2) lower HbA1c when analysed as a quan-
titative trait [8]. rs11212617 is located in a large linkage
disequilibrium (LD) block that includes other genes as well;
however, ATM is the most likely candidate to be involved
[9, 10].
In the Diabetes Prevention Program (DPP, n02,981),
there was no evidence of an association between
rs11212617 and the effect of metformin in delaying
disease progression from impaired glucose tolerance
to diabetes (CC vs AA, HR 1.22) [95% CI 0.86,
1.74] p00.27) [11]. Lack of replication is often caused
by the use of different phenotypes. As the progression
to diabetes phenotype differs markedly from the type 2
diabetes mellitus phenotype, we have attempted to
replicate our original finding in three independent
cohorts using the identical phenotypic definition to that
used in the original discovery. For this study, we used
the Diabetes Care System West-Friesland (DCS) [12]
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1972 Diabetologia (2012) 55:1971–1977and the Rotterdam Study [13] from the Netherlands,
and the multi-centre CARDS (Collaborative Atorvastatin
Diabetes Study) Trial [14] from the UK. Data were
analysed in the individual cohorts, separately and combined
in a meta-analysis. Finally an additional meta-analysis
was performed using these new cohorts combined with
the previously described GoDARTS and UKPDS stage 2
replication cohorts [8].
Methods
Study cohorts and participants Inclusion criteria for all
cohorts were: white ethnicity; continuous metformin
treatment for at least 6 months; a pretreatment HbA1c
value measured within 6 months of the start of metformin and
at least one measurement within the 18 months after; no
other glucose-lowering medication prescription except
stable sulfonylurea treatment before and during metformin
treatment. Ethics approval was obtained from the
Medical Ethics Committee of the VU Vrije Universiteit
Medical Center for the DCS, the Erasmus Medical
Center for the Rotterdam Study, and for CARDS each
centre obtained local research ethics committee approval
after approval from the Multi-centre Research Ethics
Committee. All participants gave written informed
consent.
Diabetes Care System West-Friesland The DCS started in
1996 and is a diabetes management model which aims to
improve diabetes care by coordinating the different types of
diabetes care and to improve patient empowerment by pro-
viding education. Patients from the West-Friesland region in
the Netherlands visit a local DCS centre once a year for a
medical examination; therefore longitudinal information on
medical history, drug use and drug response is available for
all patients (n05,424) [12]. Metformin response could be
defined in 929 white patients, and their characteristics are
shown in Table 1.
Patients were genotyped for rs11212617 with a Taqman
assay (Assay ID C_1314213; Applied Biosystems,
Nieuwerkerk a/d IJssel, the Netherlands) according to the man-
ufacturer’s protocol. The call rate was 97.6%, and there was no
deviation from Hardy–Weinberg equilibrium (HWE; p00.46).
Rotterdam Study The Rotterdam Study is a prospective
population-based cohort study of 10,994 whites aged
55 years and older in Rotterdam, the Netherlands. Patients
were invited between 1990 and 1999 and have been fol-
lowed since then. The aim of the study was to investigate
determinants of chronic and disabling diseases [13]. Medi-
cation prescription data were available for nearly all partici-
pants. Metformin response could be defined in 182 patients,
and their characteristics are shown in Table 1.
Participants were genotyped for rs609261, which is in
high LD with rs11212617 (r
201.0, HAPMAP, CEU) using
Table 1 Characteristics of the cohorts included in this study
Characteristic DCS Rotterdam Study CARDS
n 929 182 254
Age (years) 63.4±10.0 74.2±8.1 61.4±8.8
Male (%) 56.4 45.1 69.0
BMI 30.1±4.9 NA NA
Baseline HbA1c (%) 6.7±1.0 8.3±1.5 8.7±1.4
Baseline HbA1c (mmol/mol) 50±11 67±16 72±15
Adherence NA 88.4±14.7 NA
eGFR 91.8±36.1 NA NA
Responders (%) 67.1 57.7 52.0
Metformin monotherapy (%) 58.8 35.7 31.0
Genotype frequency rs11212617; AA/AC/CC (%) 32.5/47.1/20.4 32.4/46.7/20.9 32.3/44.4/23.2
Quality
a (selection, comparability, exposure) ****, *
b, *** ****,*
b, *** ****,*
b, ***
Data are means±SD or n (%)
aQuality of the studies assessed with the Newcastle–Ottawa Assessment Scale (www.ohri.ca/programs/clinical_epidemiology/oxford.asp); the
maximum scores for selection, comparability and exposure are ****, ** and ***, respectively. GoDARTS and UKPS are not represented in this
table and both scored the maximum of ****, ** and ***
bThe Rotterdam Study and CARDS lacked the covariates BMI and eGFR in the analysis, and the DCS lacked the covariate adherence in the
analysis, therefore these studies only scored one star for comparability
eGFR, estimated glomular filtration rate calculated with the Cockcroft–Gault formula; NA, not available
Diabetologia (2012) 55:1971–1977 1973the Illumina 550 k SNP array according to the manufac-
turer’s instructions. Quality controls were as described pre-
viously [15]. The call rate was 99.9%, and there was no
deviation from HWE (p00.75).
CARDS CARDS is a multicentre, placebo-controlled,
double-blind study that enrolled 2,838 white men and wom-
en between 40 and 75 years of age and randomised them to
receive 10 mg/day of atorvastatin or placebo [14]. Patients
had type 2 diabetes as well as one other risk factor for
coronary heart disease. CARDS was carried out in 132
centres in the UK and Ireland. Metformin response as de-
fined above could be characterised in 254 patients, and their
characteristics are shown in Table 1.
DNA was genotyped at Perlegen Sciences (Mountain
View, CA, USA) using a proprietary SNP set comprising
599164 SNPs. The call rate for rs11212617 was 99%, and
there was no deviation from HWE (p00.1).
Statistical analysis Two different outcomes were used to
measure the metformin treatment response: (1) the ability
to reach the treatment target of HbA1c ≤7 % (53 mmol/mol),
analysed with logistic regression; (2) the decrease in HbA1c
achieved, analysed as a quantitative trait with linear regres-
sion. In each cohort, the total group of metformin users was
analysed, but also a separate analysis was performed on
patients starting metformin monotherapy or those starting
dual therapy (where metformin is added to stable sulfonyl-
urea treatment). Furthermore, two separate analyses were
performed, the first on the total patient group regardless of
the baseline HbA1c, and the second using only individuals
with a baseline HbA1c >7 % (53 mmol/mol). The definition
of the endpoints and covariates was similar to the original
publication [8]. The covariates that were included in both
the logistic and linear regression analyses were: baseline
HbA1c, time between baseline HbA1c and metformin start
date, drug adherence, daily dose and creatinine clearance, if
measured in the cohort. In all cohorts with genome-wide
association study data available, principal component analy-
sis was used to exclude participants of non-white origin. A
priori power calculations using Quanto software (http://
hydra.usc.edu/gxe) based on the ORs obtained in our orig-
inal publication (1.35 or 1.25 when only stage 2 replication
data are included) showed that we had respectively 86% and
61% power in the DCS, 29% and 18% in the Rotterdam
Study, and 39% and 24% in CARDS (α00.05). Data were
considered to be significant at p<0.05.
Meta-analysis The three cohorts described above were in-
cluded in the meta-analyses of treatment success and treat-
ment HbA1c. To assess the overall robustness of the
association, a second set of meta-analyses was performed
by also including the stage 2 replication cohorts previously
described by Zhou et al: GoDARTS (n01,965) and UKPDS
(n01,113). To avoid an overestimation of the effect of the
SNP, the initial GoDARTS discovery cohort, which showed
a very strong and highly significant association with treat-
ment success (OR 1.64; 95% CI 1.37, 1.99), was not in-
cluded. The DPP Study was not included because of the
substantial nature of the difference in the phenotype [11].
For meta-analysis, a fixed-effects model was used. The
inconsistency index I
2 was used to assess between-study
heterogeneity. To assess bias, funnel plots were generated,
and Egger and Harbord tests were performed for, respec-
tively, the linear and the logistic model. The meta-analysis
was performed using Comprehensive Meta-analysis soft-
ware (Biostat, Englewood, NJ, USA) and Stata software
version 11.2 (Stata, College Station, TX, USA).
Results
The minor allele and genotype frequencies of the SNP,
rs11212617, were similar in the three new cohorts (p>0.2)
and consistent with those reported for the GoDARTS and
UKPDS cohorts. The minor allele frequency was 0.44, and
the genotype frequencies are shown in Table 1.
In the DCS cohort, including both patients receiving
monotherapy and patients receiving dual therapy, we ob-
served, as in our original publication, an association be-
tween the minor C allele of rs11212617 and treatment
success on metformin (OR 1.27 [95% 1.03, 1.58],
p00.028; Table 2). In the Rotterdam Study, we observed a
similar but non-significant trend (OR 1.45 [95% CI 0.87,
2.39], p00.15), but this was not seen in the CARDS cohort
(OR 1.03 [95% CI 0.68, 1.57], p00.86). In all three cohorts,
the effect of rs11212617 was larger in those receiving
monotherapy compared with dual therapy (Table 2). In the
analysis of on-treatment HbA1c as a quantitative trait, there
was no significant effect on HbA1c in either the DCS or the
Rotterdam Study cohort. The only significant association
was observed in the dual therapy group of the CARDS
cohort, where the C allele was associated with higher-
treatment HbA1c (Table 3). There was no association be-
tween rs11212617 genotype and baseline HbA1c in any of
the cohorts (data not shown).
In the meta-analysis of the three cohorts, there was an
increase in the odds of treatment success with the presence
of the C allele (OR 1.24, p00.016), in the whole group and
where restricted to those starting metformin monotherapy
alone (OR 1.38, p00.015). These results are consistent in
size and direction with our previous publication, such that a
combined meta-analysis including the GoDARTS and
UKPDS stage 2 replication datasets from that publication
resulted in a combined OR of 1.25 (95% CI 1.13, 1.38),
p07.8×10
−6; I
200.0%, p00.74; pHarbord00.505 (Table 2,
1974 Diabetologia (2012) 55:1971–1977Table 2 Logistic regression
for the ability to reach the
metformin treatment target of
HbA1c <7 % (53 mmol/mol)
according to the ATM
rs11212617 genotype
Patientsareincludedregardlessof
their baseline HbA1c. Additive
logistic regression models were
used to calculate the C-allelic OR
in each cohort. Covariates
included were baseline HbA1c,
baseline gap (except DCS), daily
dose, drug adherence (except for
DCS and CARDS), and eGFR
(except for CARDS and Rotter-
dam Study). In the meta-analysis,
a fixed-effects model was used
Study Group n OR (95% CI) SE p value
DCS Total group 929 1.27 (1.03, 1.58) 0.14 0.028
Monotherapy 547 1.32 (0.99, 1.78) 0.19 0.062
Dual therapy 382 1.20 (0.87, 1.66) 0.19 0.26
Rotterdam Study Total group 182 1.44 (0.87, 2.39) 0.36 0.15
Monotherapy 65 1.97 (0.72, 5.42) 0.19 0.19
Dual therapy 117 1.40 (0.77, 2.57) 0.30 0.27
CARDS Total group 254 1.03 (0.68, 1.57) 0.21 0.86
Monotherapy 81 1.50 (0.76, 2.95) 0.34 0.23
Dual therapy 173 0.82 (0.46, 1.46) 0.29 0.51
Meta-analysis Total group 1,365 1.24 (1.04, 1.49) 0.09 0.016
Monotherapy 693 1.38 (1.07, 1.80) 0.13 0.015
Dual therapy 672 1.15 (0.89, 1.48) 0.13 0.29
Meta-analysis including stage 2 replication cohorts previously used by Zhou et al [8]
GoDARTS Total group 1,965 1.21 (1.05, 1.38) 0.07 0.008
Monotherapy 1,460 1.25 (1.07, 1.46) 0.08 0.005
Dual therapy 505 1.08 (0.84, 1.40) 0.13 0.54
UKPDS Total group 1,113 1.37 (1.10, 1.72) 0.11 0.006
Monotherapy 284 1.82 (1.20, 2.78) 0.21 0.005
Dual therapy 829 1.23 (0.94, 1.62) 0.14 0.13
Meta-analysis Total group 4,443 1.25 (1.13, 1.38) 0.05 7.8×10
−6
Monotherapy 2,437 1.33 (1.16, 1.50) 0.07 1.4×10
−5
Dual therapy 2,006 1.15 (0.99, 1.34) 0.08 0.067
Table 3 Linear regression for
treatment HbA1c per ATM allele
Patientsareincludedregardlessof
their baseline HbA1c.A na d d i t i v e
linear regression model was used
to calculate the per C allele
change in treatment HbA1c (%).
Covariatesincludedwerebaseline
HbA1c, baseline gap (except
DCS), daily dose, drug adherence
(except for DCS and CARDS),
and eGFR (except for CARDS
and Rotterdam Study). The
p value of the genotype effect is
given. In the meta-analysis, a
fixed-effects model was used
Study Group n Beta (95% CI) SE p value
DCS Total group 929 −0.020 (−0.095, 0.054) 0.038 0.59
Monotherapy 547 0.026 (−0.065, 0.117) 0.046 0.58
Dual therapy 382 −0.082 (−0.209, 0.045) 0.065 0.21
Rotterdam Study Total group 182 −0.053 (−0.205, 0.098) 0.077 0.49
Monotherapy 65 −0.107 (−0.327, 0.113) 0.112 0.33
Dual therapy 117 −0.069 (−0.266, 0.127) 0.100 0.49
CARDS Total group 254 0.163 (−0.031, 0.334) 0.082 0.06
Monotherapy 81 −0.091 (−0.414, 0.213) 0.160 0.54
Dual therapy 173 0.286 (0.089, 0.476) 0.100 0.005
Meta-analysis Total group 1,365 0.001 (−0.061, 0.062) 0.032 0.99
Monotherapy 693 −0.000 (−0.082, 0.081) 0.041 0.99
Dual therapy 672 0.004 (−0.089, 0.098) 0.048 0.92
Meta-analysis including stage 2 replication cohorts previously used by Zhou et al [8]
GoDARTS Total group 1,965 −0.071 (−0.129, −0.014) 0.030 0.016
Monotherapy 1,460 −0.080 (−0.147, −0.013) 0.034 0.020
Dual therapy 505 −0.060 (−0.170, 0.050) 0.057 0.29
UKPDS Total group 1,113 −0.123 (−0.228, −0.019) 0.053 0.021
Monotherapy 284 −0.286 (−0.465, −0.107) 0.091 0.001
Dual therapy 829 −0.067 (−0.193, 0.058) 0.064 0.30
Meta-analysis Total group 4,443 −0.050 (−0.089, −0.010) 0.020 0.013
Monotherapy 2,437 −0.066 (−0.116, −0.017) 0.025 0.009
Dual therapy 2,006 −0.033 (−0.095, 0.029) 0.001 0.29
Diabetologia (2012) 55:1971–1977 1975Fig. 1a, electronic supplementary material [ESM] Fig. 1).
When the analysis was restricted to those with a baseline
HbA1c >7.0 % (53 mmol/mol), similar results were obtained
(ESM Table 1). In the meta-analysis of the three novel
cohorts where HbA1c reduction was assessed as a quantita-
tive trait, there was no significant effect of rs11212617 on
HbA1c reduction, partly because of the CARDS data being
in the opposite direction to the other two cohorts, as reported
previously (Fig. 1b). In the combined meta-analysis of all
five replication cohorts from this and our previous study, the
C allele was associated with an HbA1c decrease of −0.050
(95 % CI −0.089, −0.010) per copy of the C allele (p00.013;
I
2059%, p00.05; pEgger00.44; Table 3,F i g .1b,E S M
Fig. 1b). Again, when the analysis was restricted to those
with a baseline HbA1c above 7.0 % (53 mmol/mol), similar
results were obtained (ESM Table 2).
Discussion
In this study, we show replication of the reported association
between a SNP at a locus that includes the ATM gene and
glycaemictreatmentsuccesswithmetforminintheDutchDCS
cohort [8]. We noted a similar, although non-significant, trend
inthesmallerRotterdamStudy,butthistrendwasnotobserved
in another small study, CARDS. Meta-analysis of data from
these cohorts, which, despite intrinsic differences, provide
clear, directionally consistent effects and shows replication of
the previously reported association [8].
Importantly the effect of the SNP on metformin treatment
success was observed in most cohorts, while there was no
evidence for bias, and the characteristics of the cohorts
differ, including data from population-based cohorts, pro-
spective cohorts and clinical trials, indicating that the effect
and its size are robust across European white populations.
Furthermore, it is important to note that the association with
treatment success is present regardless of baseline HbA1c,
providing further evidence for the robustness of this
observation.
The effect in the monotherapy group is larger than in the
dual therapy group, as observed in the previous study. The
underlying mechanism of this observation is unknown. As
metformin is the recommended first-line therapy, patients
receiving metformin monotherapy are probably earlier in
their disease process. Accordingly, the observed difference
between mono and dual therapy might be explained by the
negative effects of prolonged disease duration on treatment
efficacy. However, it might also be that sulfonylurea therapy
antagonises some of metformin’s effects mediated through
mTOR-dependent and -independent signalling, as has been
suggested recently by Wang et al [16]. Further research is
required to elucidate the exact underlying mechanism.
The effect of the SNP on the ability to achieve HbA1c
≤7 % (53 mmol/mol) is stronger than the quantitative HbA1c
reduction, yet the quantitative trait should have greater
statistical power. One possible explanation for the ‘treat-to-
target’ model appearing to be better is that the patients and
clinicians aiming for a particular target may not intensify
treatment further once it is achieved. The low baseline
HbA1c of 6.7 % (50 mmol/mol) in the DCS probably reflects
increased awareness of diabetes among patients and care-
givers and current prescribing practice, where metformin is
introduced immediately after diagnosis and based on fasting
glucose rather than HbA1c [17]. This most likely explains
the lack of a genotype effect on HbA1c reduction in this
cohort, as there is not much scope for the absolute HbA1c to
decrease on metformin initiation.
Overall
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Fig. 1 Association between rs11212617, metformin treatment re-
sponse and treatment HbA1c in different cohorts. The grey squares
and horizontal lines indicate (a) the cohort-specific ORs and 95% CI
for the ability to reach the treatment target of HbA1c ≤7% (53 mmol/
mol) and (b) the cohort-specific β-coefficients and 95% CI for the
treatment HbA1c as a continuous variable. The size of the squares is
proportional to the weights of the studies. GoDARTS and UKPDS data
were from Zhou et al [8]
1976 Diabetologia (2012) 55:1971–1977We have shown, by additional replication and meta-
analysis, that our initial report is consistent in multiple
populations, supporting the finding that variation at the
ATM locus is the most robust metformin response variant
to date. Our data further support the notion that genetic
variation does not only affect disease susceptibility, but also
affects treatment response. Given the currently sparse efforts
to elucidate the genetic architecture of type 2 diabetes treat-
ment response, our data imply that future large-scale well-
powered studies might be successful in identifying further
novel loci affecting treatment response. This is particularly
pertinent for metformin response, where the biology of its
working mechanism is not fully elucidated. It is clear that
additional research is required to establish that rs11212617
is the causal SNP and that the ATM gene is the causal gene
at this locus. In addition, it is necessary to investigate the
mechanism whereby ATM variation alters metformin
response.
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